Darius Kharabi is a co-founder of Lagunita and of Combangio, where he served as CEO and Director before its acquisition by Kala Pharmaceuticals (NASDAQ: KALA) in 2021.  He served as a Board member of Kedalion Therapeutics before its acquisition by Novartis AG in 2022 and of xCella Biosciences before its acquisition by Ligand (NASDAQ: LGND) in 2020, and is currently a Board Member of Keda Holding.  Mr. Kharabi also served as executive management for xCella and Kedalion, helping to build early value, raise financing and recruit full-time leadership teams.  Prior to Lagunita, he was Vice President, Corporate Development and International Sales at OrthAlign Inc., a commercial stage orthopedic surgery navigation company, where his responsibilities included the launch of the KneeAlign® total knee arthroplasty navigation product line in North America, Europe, Asia and Australia.  Mr. Kharabi started his career as a biotechnology licensing attorney at Wilson, Sonsini Goodrich & Rosati PC.  He received his B.S. in Biochemistry from Georgetown University and his J.D. and M.B.A. degrees from Stanford University